Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May;42(3):258-265.

In Vitro Radiosensitizing Effects of Temozolomide on U87MG Cell Lines of Human Glioblastoma Multiforme

Samira Borhani  1 , Hossein Mozdarani  2 , Somayyeh Babalui  3 , Mohsen Bakhshandeh  3 , Hassan Nosrati  3
Affiliations

In Vitro Radiosensitizing Effects of Temozolomide on U87MG Cell Lines of Human Glioblastoma Multiforme

Samira Borhani et al. Iran J Med Sci. 2017 May.

Abstract

Background: Glioma is the most common primary brain tumor with poor prognosis. Temozolomide (TMZ) has been used with irradiation (IR) to treat gliomas. The aim of the present study was to evaluate the cytotoxic and radiosensitizing effect of TMZ when combined with high-dose and high-dose rate of gamma irradiation in vitro.

Methods: Two 'U87MG' cell lines and skin fibroblast were cultured and assigned to five groups for 24, 48, and 72 hours. The groups were namely, TMZ group (2000 μM/L), IR group (5 Gy), TMZ plus IR group, control group, and control solvent group. MTT assay was applied to evaluate cell viability. Data were analyzed with SPSS 21.0 software using one-way ANOVA and Kruskal-Wallis test. P<0.05 were considered statistically significant.

Results: The slope of growth curve U87MG cells in semi-logarithmic scale was equal to 27.36±0.89 hours. The viability of cells was determined for different TMZ and IR treatment groups. In terms of cell viability, there were no significant differences between the control and control solvent groups (P=0.35) and between treated group by IR (5 Gy) alone and TMZ (2000 µM/ml) alone (P=0.15). Data obtained for the cell viability of combined TMZ plus IR in both cell lines compared to TMZ or IR treated group alone showed a significant difference (P=0.002).

Conclusion: The evaluation of cells viability showed that TMZ in combination with IR on glioma cells led to a significant radiosensitivity compared to IR alone.

Keywords: Glioblastoma; Radiation-sensitizing agents; Radiotherapy; Temozolomide.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The growth curve of U87MG cell line (cell numbers versus time). All experiments were repeated three times. Error bars indicate the standard error of means (SEM).
Figure 2
Figure 2
Viability of U87MG cells after treatment with various concentrations of TMZ assayed at values time intervals. Error bars represents the standard deviation of mean values obtained from triplicate experiments.
Figure 3
Figure 3
Viability of fibroblast cells after treatment with various concentrations of TMZ assayed at values time intervals. Error bars represents the standard deviation of mean values obtained from triplicate experiments.
Figure 4
Figure 4
Viability of U87MG cells after treatment with various concentrations of TMZ in combination with irradiation assayed at values time intervals. Error bars represents the standard deviation of mean values obtained from triplicate experiments.
Figure 5
Figure 5
Viability of fibroblast cells after treatment with various concentrations of TMZ in combination with irradiation assayed at values time intervals. Error bars represents the standard deviation of mean values obtained from triplicate experiments.
Figure 6
Figure 6
Viability of primary fibroblast and U87MG cells. Data represents the mean values obtained from triplicate experiments. Error bars indicate the standard deviation of mean values.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807–12. doi: 10.1126/science.1164382. [ PMC Free Article] - DOI - PMC - PubMed
    1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96. doi: 10.1056/NEJMoa043330. - DOI - PubMed
    1. Ushio Y, Kochi M, Hamada J, Kai Y, Nakamura H. Effect of surgical removal on survival and quality of life in patients with supratentorial glioblastoma. Neurol Med Chir (Tokyo) 2005;45:454–60. doi: 10.2176/nmc.45.454. - DOI - PubMed
    1. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003. doi: 10.1056/NEJMoa043331. - DOI - PubMed
    1. Zhang H, Gao S. Temozolomide/PLGA microparticles and antitumor activity against glioma C6 cancer cells in vitro. Int J Pharm. 2007;329:122–8. doi: 10.1016/j.ijpharm.2006.08.027. - DOI - PubMed

LinkOut - more resources